Abstract: Tumor necrosis factor a (TNFa) is a proinflammatory cytokine, and elevated levels of TNFa in serum are associated with various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis, and systemic lupus erythaematosus. TNFa performs its pleiotropic functions by binding to two structurally distinct transmembrane receptors, TNF receptor (TNFR) 1 and TNFR2. Antibody-based therapeutic strategies that block excessive TNFa signaling have been shown to be effective in suppressing such harmful inflammatory conditions. Golimumab (SimponiV R ) is an FDA-approved fully human monoclonal antibody targeting TNFa that has been widely used for the treatment of RA, AS, and CD. However, the structural basis underlying the inhibitory action of golimumab remains unclear. Here, we report the crystal structure of the Fv fragment of golimumab in complex with TNFa at a resolution of 2.73 Å . The resolved structure reveals that golimumab binds to a distinct epitope on TNFa that does not overlap with the binding residues of TNFR2. Golimumab exerts its inhibitory effect by preventing binding of TNFR1 and TNFR2 to TNFa by steric hindrance. Golimumab does not induce conformational changes in TNFa that could affect receptor binding. This mode of action is specific to golimumab among the four anti-TNFa therapeutic antibodies currently approved for clinical use.
A 50-75-word statement, written for a broader audience, outlining the importance and/or impact of the work presented in the manuscript: The anti-TNFa therapeutic antibody golimumab (Simponi V R ) received FDA approval in 2009 and has demonstrated robust clinical efficacy in the treatment of rheumatic disease; however the structural basis underlying its inhibitory action remains unclear. In this study, we report the crystal structure of the TNFa:golimumab complex and reveal the mode of action of golimumab, which is different from that of the other FDA-approved anti-TNFa antibodies, infliximab (Remicade V R ), adalimumab (Humira V R ), and certolizumab pegol (Cimzia V R ). 
Introduction
Tumor necrosis factor a (TNFa) is a pleiotropic cytokine involved in regulating diverse bodily functions, including cell growth modulation, inflammation, carcinogenesis, viral replication, septic shock and autoimmunity. 1 TNFa performs its functions by binding to two structurally distinct membrane receptors, TNFR1 (also known as p55) and TNFR2 (p75). 2 TNFa signaling via TNFR1 is predominantly associated with inflammation and apoptosis. In contrast, TNFR2 is mainly implicated in regulation of T-cell migration and tissue regeneration. Because of its pleiotropic actions, the biosynthesis of TNFa is under strict control of multiple and complex regulatory mechanisms, including gene transcription, mRNA turnover, translation and intracellular signaling of the protein. Dysregulation of TNFa production can result in elevated serum TNFa levels and the development of various inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease (CD), psoriasis, and systemic lupus erythaematosus. 3 Recently, therapeutic strategies that block excessive TNFa signaling have emerged to suppress these harmful inflammatory conditions. To date, the following five molecules have been approved by the FDA as effective TNFa inhibitors for clinical use and led to significant advances in autoimmune inflammatory disease therapy: infliximab (Remicade V R ; humanized chimeric monoclonal antibody (mAb) of the isotype IgG1), adalimumab (Humira V R ; fully human mAb of the IgG1/j isotype), certolizumab pegol (Cimzia V R ; PEGylated humanized Fab fragment), golimumab (Simponi V R ; fully human mAb of the IgG1/j isotype), and etanercept (Enbrel V R ; Fc-TNFR2 fusion protein). 4 These new biologic agents have changed the paradigm of RA treatment, leading to improvements in controlling the signs and symptoms of RA refractory to classical low-molecular-weight drugs such as methotrexate (MTX), and in slowing joint destruction. 5 The concentration of golimumab necessary to neutralize TNFa-induced E-selectin expression on human endothelial cells by 50% is reported to be less than those for infliximab and adalimumab. 6 Nevertheless, patients currently treated with an anti-TNFa agent may remain refractory or become nonresponsive to the treatment. 7 In addition, a sizable proportion of patients experience adverse events, such as hepatitis B infection and tuberculosis. 8 Once a primary TNFa inhibitor fails, a patient must switch to another antiTNFa agent that has a complementary mode of action or differs in its capacity to induce immunogenicity. 9 The molecular basis underlying the inhibitory mechanisms of infliximab, adalimumab and certolizumab has been elucidated in part by X-ray crystallography. [10] [11] [12] Adalimumab binds a large surface area on TNFa, with its epitope directly overlapping the TNFR2 binding area. Infliximab's epitope is located at the "shoulder" on a bell-shaped TNFa trimer and contains a smaller TNFa:TNFR2 interacting surface. Certolizumab binds to the "waist" portion on TNFa and has overlapping segments with the binding footprint of TNFR2. However, the structural basis for the inhibitory action of golimumab remains unclear.
Here, we report the crystal structure of the variable domain (Fv) fragment of golimumab in complex with TNFa at a resolution of 2.73 Å , which reveals an idiosyncratic mode of binding to TNFa to compete with TNFRs at the atomic level.
Results and Discussion
Overall structure of the TNFa:golimumab Fv complex
The soluble forms of the human TNFa and the Fv fragment of the golimumab, both of which contain intrachain disulfide bonds, were produced by a Gram-positive bacterial secretory expression. For production of the Fv fragment, the "iRAT (intervening removable affinity tag)" system was used to ensure stoichiometric expression of heavy (V H )-and light (V L )-chain variable domains followed by correct folding and assembly. 13 By employing these recombinant proteins, the TNFa:golimumab Fv complex (subsequently referred to as the TNFa:golimumab complex) was prepared. Analytical gel filtration confirmed that the stoichiometrically saturated 1: Table I ). The structure was resolved by molecular replacement using the existing TNFa apo structure (PDB code: 1A8M) 14 and pembrolizumab Fv (PDB code: 5B8C). 15 The asymmetric unit contained two copies of the TNFa homotrimer and six copies of the golimumab Fv, thus providing six copies of the TNFa:golimumab interface related by non-crystallographic symmetry (NCS). The side-chain electron density was sufficiently resolved throughout the TNFa:golimumab interface [ Supplementary Fig. S1 (D,E)].
The three-dimensional arrangement of the biologically relevant TNFa:golimumab complex has an overall shape that resembles a bell, with the TNFa trimer and the three Fv fragments sitting at the shoulder of the bell [ Fig. 1(A, left) ]. In this binding orientation, the golimumab would point away from the membrane in the membrane-bound form of TNFa, with the membrane located below the TNFa molecule in Figure 1(A, left) . Therefore, golimumab not only binds the soluble form of TNFa but also may, in principle, be able to bind to TNFa before it is released from its membrane-bound precursor. This structure-based assumption is in line with a pervious pharmacological data that golimumab IgG bind to membrane-bound TNFa with an apparent dissociation constant (K D ) of 1890 pM. 6 When viewed along the intrinsic 3-fold axis of the TNFa trimer, the biologically relevant complex resembles a three-bladed propeller, with each TNFa:Fv protomer forming one blade [ Fig. 1(A, right) S2 ). Furthermore, it cannot be assumed that the DE loop, which is situated distal to the golimumab epitope, specifically undergoes allosteric conformational changes even though proximal regions exhibit no apparent shift upon golimumab binding. Because of the high affinity of golimumab for TNFa, we assume that a stoichiometrically saturated 1:3 TNFa homotrimer:golimumab complex could be formed in vivo, although molecular populations of the 1:3 complex might not be dominant, which is similar to the cases of higher-order structures of TNFa:adalimumab and TNFa:infliximab complexes as recently shown by negative stain TEM and cryo-EM techniques. 17 However, formation of the 1:3 complexes is not necessary for inhibition of signaling via TNFRs because this type of signaling requires multiple intact TNFR-binding sites on the TNFa homotrimer, as demonstrated by inhibition of signaling when TNFa exchanges protomers with dominant-negative TNFa variants. 18 
Golimumab epitope
To establish the residues that fall within the golimumab epitope on TNFa, we analyzed the interfaces of the TNFa:golimumab complex via PISA. 19 All NCS copies share the same pattern of intermolecular contacts, which involve 13 TNFa residues and bury surface areas of 905 and 997 Å 2 on TNFa and golimumab, respectively [ Fig. 2(A) ]. These are in the typical range of the interaction surface between antibodies and protein antigens. 20 Fig. 2(B) ; Supplementary Fig. S3 ]. Arg100 H makes the largest contribution to the TNFa:golimumab interaction and presents a binding free energy of 27.7 kcal/mol as calculated with ANCHOR. 21 From the golimumab light chain, only two residues, Tyr30 L and Tyr32 L in CDR-L1, are involved in the interaction with Gly24 T (AA' loop) and Asp140 T (GH loop), respectively. Notably, the TNFa residues interacting with golimumab CDRs are distinct from those that engaged TNFR2 [ Fig. 2(A) and Supplementary Fig.  S3 ]. A previous crystallographic study of the TNFa:TNFR2 complex (PDB code: 3ALQ) showed that the cysteine-rich domain 2 (CRD2) and CRD3 of TNFR2 have contacts with residues in the AA' loop (Gln21 
TNFR steric competition properties of golimumab
Because golimumab inhibition of TNFR binding could not arise from direct competition for receptorbinding residues on TNFa and/or potential golimumab-induced conformational changes in TNFa, steric clashes caused by physical overlap between the bound golimumab and TNFRs could be substantial and critical to golimumab's inhibitory activity. To gain quantitative insights into the effect of inhibitor overlap on blocking TNFa interactions with TNFRs, we calculated the theoretical volumes of atomic overlap between golimumab and TNFR2. First, we performed a structural alignment of the TNFa:golimumab complex with the TNFa:TNFR2 complex. We then calculated the volumes of atomic overlap between the superimposed golimumab and TNFR2 (Fig. 3) . Similar analyses were also performed for infliximab [ Supplementary Fig. S4(A,B) ], adalimumab [ Supplementary Fig. S4(C,D) ], and certolizumab [ Supplementary Fig. S4(E,F) Furthermore, the atomic overlapping volumes between anti-TNFa antibodies and TNFR1 were calculated. Because the structure of the TNFa:TNFR1 complex has not been determined, we used the Fig. S5 ). This steric conflict between golimumab and TNFR1 underlies, in part, the therapeutic efficacy of golimumab, which has strong inhibitiory effects on TNFa-binding to TNFR1 and presents an IC 50 of 3.9 ng/mL as previously described. 6 Interestingly, golimumab's physical overlapping volumes with the two TNFRs are drastically different. Such a disparity is not observed for the other three anti-TNFa antibodies. However, given that even a small overlapping volume between the receptor and the antibody can cause steric repulsion, it is clear that golimumab exhibits competitive inhibitory action against both TNFR1 and TNFR2. Previous functional analyses of TNFRs have demonstrated the predominant role of TNFR1 in the pathogenesis and exacerbation of inflammation. 23, 24 Moreover, TNFR2 has been shown to be crucial for the proliferation, activation and antigen presentation of T-cells, which are essential in cell-mediated immune responses against bacteria and viruses. 25 Blocking all effect of TNFRs signaling can therefore be counter-productive. Clinical trials have assessed the side effects of golimumab treatment and reported an increased risk of infections, reactivation of tuberculosis, invasive fungal infections, and other opportunistic infections. 26, 27 These adverse drug reactions can be explained in part by our finding that golimumab sterically hinders TNFR2 as well as TNFR1 from associating with TNFa (Figs. 3  and 4) . In summary, structural analysis of the TNFa:golimumab complex and its comparison to the TNFa:TNFR2 complex revealed that the binding footprints of golimumab and TNRF2 on TNFa do not overlap at all; however, steric clashes between the bound golimumab and TNFRs are critical to its inhibitory activity. Golimumab does not induce conformational changes in TNFa that could affect receptor binding. This mode of action of golimumab is different from that of the other currently approved anti-TNFa therapeutic antibodies, infliximab, adalimumab, and certolizumab pegol. Our findings may provide structure-based insights to guide engineering efforts to create even more efficient versions of anti-TNFa biologics.
Materials and Methods
Complete amino-acid sequence of the expression constructs
The cloned Homo sapiens TNFa sequence contains residues 77-233 of the 233 total residues (UniProt accession number: P01375), with the FLAG-tagged at the N-terminus underlined and additional Cterminal residues retained after restriction site cloning or tobacco etch virus (TEV) cleavage shown in italics (refer to the following section for cloning details): DYKDDDDKVRSSSRTPSDKPVAHVVANPQAEG QLQWLNRRANALLANGVELRDNQLVVPSEGLYLIY SQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLS AIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGD RLSAEINRPDYLDFAESGQVYFGIIALTSENLYFQ
The golimumab light chain variable region (V L ), with the additional N-and C-terminal residues retained after restriction site cloning or TEV cleavage shown in italics is as follows:
The golimumab heavy chain variable region (V H ), with the additional N-terminal residues retained after restriction site cloning or TEV cleavage shown in italics is as follows: 
SKLQVQLVESGGGVVQPGRSLRLSCAASGFIFSS

YAMHWVRQAPGNGLEWVAFMSYDGSNKKYADSV KGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARD RGIAAGGNYYYYGMDVWGQGTTVTVSS
Protein expression and purification
The soluble form of TNFa was produced by secretion from the Gram-positive bacterium Brevibacillus choshinensis. 13 The artificially synthesized codonoptimized cDNA of TNFa was inserted downstream of and in frame with the secretion signal sequence of the plasmid pNY326 (Clontech). To facilitate the detection and purification of the secreted proteins, sequences for the TEV protease cleavage site and a His 6 tag were placed at the C-termini of the TNFa cDNAs. B. choshinensis cells harboring the TNFaexpression plasmid were grown at 308C with shaking at 200 rpm in 2SY medium (soytone 40 g/L, yeast extract 5 g/L, glucose 20 g/L, and CaCl 2 0.15 g/L) supplemented with 50 mg/L neomycin for 65-70 h. The recovered culture supernatant was adjusted to a final ammonium sulfate concentration of 60% saturation. The precipitate was pelleted, dissolved in TBS buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl), and dialyzed overnight against the same buffer. The dialyzed sample was purified with Ni-NTA resin, mixed with TEV-His 6 and dialyzed overnight again against TBS buffer. The cleaved His 6 tag and TEV-His 6 were removed using a HisTrap column. The flow-through fractions were further purified with a HiLoad 16/60 Superdex 75 column (GE Healthcare). The golimumab Fv was expressed and purified using the iRAT system as previously described. 13 
Crystallization
The protein complex was prepared by incubating TNFa with golimumab Fv at a molar ratio of 1:6 for 1 h on ice. The complex was subjected to size exclusion chromatography (Superdex 200 10/300 column, GE Healthcare). Peak fractions containing the TNFa:golimumab Fv complex were concentrated to approximately 10 mg/mL by ultrafiltration (Millipore, MWCO 50 kDa) and used for crystallization experiments. The crystals of the complex used for structural determination were grown at 208C by hanging drop vapor diffusion. A 400 lL reservoir containing 0.1 M sodium acetate (pH 4.6) and 1.4 M NaCl was equilibrated against a 2 lL drop containing a 1:1 mixture of the complex and reservoir solution. After 14-21 days of growth, the crystals were cryo-protected in 25% ethylene glycol in the mother liquor and then flash-frozen in liquid nitrogen.
Data collection, structure determination and analysis
The diffraction data were collected at 100 K at the SPring-8 beamline BL41XU (Japan) using a PILATUS3 6M detector. The data were then integrated and scaled using XDS. 28 The structure of the TNFa:golimumab Fv complex was determined by molecular replacement with the program MR-PHASER 29 using the atomic coordinates of the human TNFa apo structure (PDB code: 1A8M) and the pembrolizumab Fv (PDB code: 5B8C) as the search models. The model was further rebuilt in COOT 30 and refined with phenix.refine 31 (Table I ). In the final Ramachandran plot, 95.6% and 4.1% of residues were in the favored and allowed regions, respectively. The refined structures were visualized with PyMOL (http://www.pymol.org/). The PISA server 19 was used to identify protein-protein interactions and estimate the solvent-accessible surface area. The model complex of TNFa:TNFR1 was constructed based on the structural alignment of the LTa (TNFb):TNFR1 complex (PDB code: 1TNR) 22 and the TNFa:TNFR2 complex (PDB code: 3ALQ) 16 using a superimposing program in UCSF Chimera. 32 The volumes of physical overlap of each anti-TNFa antibody with TNFRs were calculated by the volumes tool in Chimera.
